<DOC>
	<DOC>NCT01892904</DOC>
	<brief_summary>The is a multi-center, randomized, open-label, active-controlled, parallel-group comparative study (24-week treatment period). The objective of this study is to prove the superiority of BAY 86-5300 with flexible extended regimen for treatment of dysmenorrhea to BAY 86-5300 with 28-day cyclic regimen in terms of primary efficacy variable, number of days with dysmenorrheic pain over 140 days of evaluation period. In addition, the long-term safety of the flexible extended regimen of BAY86-5300 in patients treated for one year will be investigated.</brief_summary>
	<brief_title>Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Dysmenorrhea patients with a total dysmenorrhea score (sum of the two subscores: severity of dysmenorrhea and use of analgesics) of at least 3 points in each of the last two menstruations before randomization (baseline observation phase) Patients with dysmenorrheic pain during the 2 baseline cycles before randomization. Dysmenorrheic pain means any spasmodic pelvic pain or lower abdominal pain with possible radiation towards back or thighs recorded in the Patient Diary in correspondence with a withdrawal and/or menstrual bleeding episode. Pain could start up to 2 days before the onset of the bleeding episode the bleeding and terminates on the last day of bleeding of before Patients having the regular cyclic menstrual period (25 to 38 days) in the latest two menses before randomization (baseline observation phase) Willingness to use a barrier method (i.e., nonhormonal method) for contraception during the study. Acceptable methods of contraception include (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intrauterine device. Patients who have organic diseases of which surgical treatment is prioritized by the investigator Patients aged 40 years or older with ovarian chocolate cysts being more than 10 cm in size of the longest diameters Patients with ovarian chocolate cysts having solid part in the cyst Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese Labeling)</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>YAZ</keyword>
	<keyword>Flexible regimen</keyword>
	<keyword>Drospirenone</keyword>
	<keyword>Ethinylestradiol Betadex</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Japanese patients</keyword>
</DOC>